PHARMACEUTICALS see also Drugs

Amendments

FDA: strengthen regulation of compounding drugs by pharmacies (S. 959), S6080, S6081 [30JY]

——— strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), S7683, S7684 [30OC], S8008 [13NO], S8026, S8057 [14NO]

Articles and editorials

Cancer Clinics Are Turning Away Thousands of Medicare Patients—Blame the Sequester, H2318 [25AP]

Bills and resolutions

Animals: condemn practice of gassing stray cats and dogs (see H. Res. 433), H7567 [5DE]

——— disapprove use of gas chambers to euthanize shelter animals and support State laws requiring the use of drugs for euthanasia by animal shelters (see H. Res. 208), H2533 [8MY]

Business and industry: clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers (see S. 1128), S4212 [11JN] (see H.R. 2315), H3287 [11JN]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 214), S469 [4FE] (see H.R. 3709), H7687 [11DE]

Contraceptives: establish certain duties for pharmacies to ensure provision of FDA-approved contraception (see S. 333), S772 [14FE] (see H.R. 728), H546 [14FE]

Cuba: facilitate export of U.S. agricultural products, remove impediments to export of medical devices and medicines, allow travel by U.S. citizens, and establish an agricultural export promotion program (see H.R. 873), H701 [27FE]

Dept. of HHS: amend and reauthorize the Controlled Substance Monitoring Program (see H.R. 3528), H7187 [18NO]

——— award certain asthma-related grants to States that permit trained school personnel to administer epinephrine (see S. 1503), S6446 [12SE] (see H.R. 2094), H2910 [22MY]

——— conduct or support a comprehensive study comparing total health outcomes, including risk of autism, in vaccinated populations and unvaccinated populations (see H.R. 1757), H2351 [25AP]

——— grant provisional approval to fast-tracked drugs used in therapies and treatments for life-threatening diseases (see H.R. 2090), H2910 [22MY]

——— limit copayment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the amount applicable to drugs in a non-preferred brand drug tier (see H.R. 460), H341 [4FE]

——— prevent abuse of dextromethorphan by restricting over-the-counter sales and bulk distribution (see S. 644), S2146 [21MR]

——— promulgate regulations on patient medication information to ensure patients receive consistent and high-quality information about prescription drugs (see S. 752), S2749 [17AP] (see H.R. 1608), H2124 [17AP]

——— provide for public disclosure of charges for certain hospital and ambulatory surgical center treatment episodes (see H.R. 2853), H5173 [30JY]

Dept. of Justice: provide the Depts. of Defense and Veterans Affairs authority to establish a prescription drug take-back program for Armed Forces members and veterans (see S. 1089), S3954 [4JN] (see H.R. 3714), H8107 [12DE]

Dept. of Veterans Affairs: provide for certain requirements relative to immunization of veterans (see S. 1165), S4481 [13JN]

Diseases: de-link research and development incentives from drug prices for new medicines to treat HIV/AIDS and stimulate greater sharing of scientific knowledge (see S. 626), S2026 [20MR]

——— preserve effectiveness of medically important antimicrobials used in treatment of human and animal diseases (see S. 1256), S5498 [27JN] (see H.R. 1150), H1425 [14MR]

——— reduce disparities and improve access to diagnosis and treatment of prostate cancer for underserved populations and men with a family history of prostate cancer (see S. 516), S1592 [11MR]

——— require group and individual health insurance coverage and group health plans to cover oral cancer drugs on terms no less favorable than for cancer medications administered by a health care provider (see S. 1879), S9052 [19DE] (see H.R. 1801), H2392 [26AP]

Drugs: establish a commission to coordinate efforts to reduce prescription drug abuse (see S. 1277), S5620 [10JY]

——— exempt real property from civil forfeiture due to medical-marijuana-related conduct authorized by State law (see H.R. 784), H595 [15FE]

——— increase Federal oversight of prescription opioid treatment and assistance to States in reducing opioid abuse, diversion, and deaths (see S. 348), S772 [14FE] (see H.R. 672), H501 [13FE]

——— make any substance containing hydrocodone a schedule II drug under the Controlled Substances Act (see S. 621), S2026 [20MR] (see H.R. 1285), H1718 [20MR]

——— provide an affirmative defense for medical use of marijuana in accordance with the laws of the States (see H.R. 710), H545 [14FE]

——— reduce prescription drug misuse and abuse (see S. 1657), S7876 [6NO]

——— reschedule marijuana under the Controlled Substances Act and allow for medicinal use of marijuana in accordance with State laws (see H.R. 689), H545 [14FE]

EPA: allow for the distribution, sale, and consumption of remaining inventories of over-the-counter chlorofluorocarbon (CFC) epinephrine inhalers (see H.R. 1220), H1547 [15MR]

FDA: approve certain drugs and biological products for use in a limited population of patients to address increases in bacterial and fungal resistance to drugs and biological products (see H.R. 3742), H8108 [12DE]

——— encourage use of abuse-deterrent formulations of drugs (see S. Res. 97), S2649 [15AP] (see H. Res. 161), H2026 [15AP]

——— ensure valid generic drugs may enter the market (see S. 504), S1269 [7MR]

——— exempt certain user fees from budget sequestration (see S. 1413), S6126 [31JY] (see H.R. 2725), H4724 [18JY]

——— modify approval of any drug containing controlled-release oxycodone hydrochloride to limit such approval to use for relief of severe-only pain (see H.R. 1366), H1823 [21MR]

——— permit the sale of, and access to, ‘‘research use only’’ products in diagnostic tests (see H.R. 3005), H5397 [2AU]

——— prohibit wholesalers from purchasing prescription drugs from pharmacies and enhance information and transparency of drug wholesalers engaged in interstate commerce (see H.R. 1958), H2602 [14MY]

——— provide incentives for the development of new combination drugs (see H.R. 2985), H5396 [2AU]

——— reauthorize user fee programs relating to generic new animal drugs (see H.R. 1408), H1856 [9AP]

——— reauthorize user fee programs relating to new animal drugs (see H.R. 1407), H1856 [9AP]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (see S. 622), S2026 [20MR]

——— require the label of drugs to contain a parenthetical statement identifying the source of any ingredient constituting or derived from a grain or starch-containing ingredient (see H.R. 2003), H2654 [15MY]

——— strengthen and secure the pharmaceutical distribution supply chain to protect consumers from counterfeit pharmaceuticals (see S. 957), S3531 [15MY] (see H.R. 1919), H2567 [9MY]

——— strengthen regulation of compounding drugs by pharmacies (see S. 959), S3531 [15MY] (see H.R. 2186), H2954 [23MY] (see H.R. 3019), H5397 [2AU] (see H.R. 3089), H5546 [12SE]

——— strengthen regulation of human drug compounding and drug supply chain security (see H.R. 3204), H5921 [27SE]

——— waive or reduce certain fees applicable to generic drug facilities if such fees present a significant barrier to market entry due to limited resources or other circumstances (see H.R. 3631), H7394 [2DE]

Federal employees: ensure Federal Employees Health Benefit Program integrity, transparency, and cost savings in the pricing and contracting of prescription drug benefits (see H.R. 1367), H1823 [21MR]

FEMA: codify authority to use Urban Areas Security Initiative and State Homeland Security Grant Program funding for enhancing medical preparedness, medical surge capacity, and mass prophylaxis capabilities (see H.R. 1791), H2391 [26AP]

Government regulations: allow personal importation and reimportation of prescription drugs (see H.R. 3715), H8107 [12DE]

Health: enhance efforts to address antimicrobial resistance (see H.R. 2285), H3250 [6JN]

——— incentivize the development of abuse-deterrent drugs (see H.R. 486), H342 [4FE]

——— promote development of meaningful treatments for patients (see H.R. 3091), H5546 [12SE] (see H.R. 3116), H5588 [17SE]

——— reform medical liability system, improve access to health care for rural and indigent patients, and enhance access to affordable prescription drugs (see S. 1860), S9051 [19DE]

Medicaid: remove exclusion from medical assistance of items and services for patients in mental institutions (see H.R. 2757), H4825 [19JY]

Medicare: adjust part B and D premiums for high-income beneficiaries (see S. 1198), S4792 [20JN]

——— allow retail community pharmacies to deliver diabetic testing supplies to beneficiaries (see H.R. 2845), H5093 [26JY]

——— apply exceptions process fairly for tiered formulary drugs in prescription drug plans (see S. 1365), S5968 [25JY] (see H.R. 2827), H5088 [25JY]

——— authorize the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (see S. 77), S213 (see S. 117), S214 [23JA]

——— count the negotiated price of drugs provided free or at nominal charge under compassionate treatment programs towards incurred out-of-pocket costs (see H.R. 1239), H1567 [18MR]

——— cover supplies associated with insulin injection, home needle removal, decontamination, and disposal devices, and disposal of needles and syringes through a sharps-by-mail or similar program (see S. 672), S2500 [9AP] (see H.R. 2977), H5344 [1AU]

——— deliver a meaningful drug benefit and lower prescription drug prices (see S. 408), S1011 [28FE] (see H.R. 928), H815 [28FE]

——— eliminate delay in including oral-only end-stage renal disease-related drugs in the prospective payment system (see H.R. 413), H281 [23JA]

——— encourage use of dispensing techniques that foster efficiency and reduce wasteful dispensing of outpatient prescription drugs in long-term care facilities (see S. 1493), S6327 [10SE]

——— exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals (see S. 806), S2960 [24AP] (see H.R. 800), H596 [15FE]

——— extended coverage of immunosuppressive drugs for kidney transplant patients and other renal dialysis provisions (see S. 323), S708 [13FE]

——— improve access to medication therapy management under part D (see S. 557), S1785 [13MR]

——— include information on the coverage of intensive behavioral therapy for obesity in the ‘‘Medicare and You Handbook’’ and coordinate programs to prevent and treat obesity (see S. 1184), S4673 [19JN] (see H.R. 2415), H3758 [18JN]

——— permit direct payment to pharmacies for certain compounded drugs for a specific beneficiary for use through an implanted infusion pump (see S. 914), S3326 [9MY] (see H.R. 232), H84 [14JA]

——— prevent budget sequestration from impacting payment for physician-administered drugs (see H.R. 1416), H1856 [9AP]

——— provide eligible individuals with single chronic diseases access to medication therapy management under the part D prescription drug program (see H.R. 1024), H1327 [7MR]

——— provide entitlement to immunosuppressive drugs for kidney transplant recipients (see H.R. 1325), H1821 [21MR] (see H.R. 1428), H1856 [9AP]

——— provide for a prescription drug plan safety program to prevent fraud and abuse in the dispensing of controlled substances (see H.R. 3392), H6951 [30OC]

——— provide for pharmacy benefits manager standards under the prescription drug program, establish basic audit standards and transparency of payment methodology of pharmacies, and provide recoupment returns (see S. 867), S3091 [6MY]

——— require drug manufacturers to provide rebates for drugs dispensed to low-income individuals under the prescription drug benefit program (see S. 740), S2684 [16AP] (see H.R. 1588), H2066 [16AP]

——— require sponsors of prescription drug plans to implement procedures to prevent fraud and abuse (see H.R. 2960), H5343 [1AU]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (see H.R. 1102), H1357 [12MR]

Mental health: reauthorize and improve programs related to mental health and substance use disorders (see S. 689), S2501 [9AP]

Patient Protection and Affordable Care Act: repeal amendments which disqualify expenses for over-the-counter drugs under health savings accounts and health flexible spending arrangements (see S. 1647), S7829 [5NO] (see H.R. 2835), H5088 [25JY]

Pharmacies: ensure and foster safety and quality of care and competitive marketplace by exempting independent pharmacies from antitrust laws in negotiations with health and health insurance providers (see H.R. 1188), H1426 [14MR]

Research: provide incentives for investment in research and development for new medicines and enhance access to new medicines (see S. 627), S2026 [20MR]

Sabin Vaccine Institute: anniversary (see H. Res. 114), H1396 [13MR]

Schools: prohibit Federal education funding for elementary or secondary schools that provide access to emergency postcoital contraception (see H.R. 2943), H5343 [1AU]

Social Security: prevent fraud and abuse in Medicare, Medicaid, and State Children’s Health Insurance Program and require National Provider Identifiers for reimbursement of prescriptions under Medicare part D (see H.R. 2828), H5088 [25JY]

——— reform (see H.R. 1374), H1824 [21MR]

Sports: improve integrity and safety of interstate horseracing (see S. 973), S3569 [16MY] (see H.R. 2012), H2716 [16MY]

Taxation: deny any deduction for direct-to-consumer advertisements of prescription drugs (see H.R. 923), H815 [28FE]

——— include vaccines against seasonal influenza within the definition of taxable vaccines (see S. 391), S943 [27FE] (see H.R. 475), H341 [4FE]

Veterinarians: allow transport and dispensing of controlled substances in the usual course of veterinary practice outside of the registered location (see S. 950), S3430 [14MY] (see S. 1171), S4521 [17JN] (see H.R. 1528), H1991 [12AP]

Cloture motions

FDA: strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), motion to proceed, S7923 [7NO], S7949 [12NO], S8027 [14NO]

Letters

Medicare and Medicaid budget cuts: Alliance for a Just Society, S1017 [28FE]

Medicare Prescription Drug Savings and Choice Act: Max Richtman, National Committee To Preserve Social Security & Medicare, S1018 [28FE]

Safeguarding America’s Pharmaceuticals Act: several organizations, H2982, H2983 [3JN]

——— Stanley C. Weisser, California State Board of Pharmacy, H2981 [3JN]

Lists

Organizations supporting H.R. 3204, Drug Quality and Security Act, S8028 [14NO]

Staff and Senators who worked on H.R. 3204, Drug Quality and Security Act, S8025 [14NO]

Motions

FDA: strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), S7841 [6NO], S7891 [7NO], S7937 [12NO], S7973 [13NO], S8026 [14NO]

Remarks in House

American Pharmacists Month: observance, E1718 [20NO]

Business and industry: clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers (H.R. 2315), unanimous-consent agreement, H5055 [25JY]

Contraceptives: establish certain duties for pharmacies to ensure provision of FDA-approved contraception (H.R. 728), E148 [14FE]

Dept. of HHS: award certain asthma-related grants to States that permit trained school personnel to administer epinephrine (H.R. 2094), H5145–H5147 [30JY]

——— conduct or support a comprehensive study comparing total health outcomes, including risk of autism, in vaccinated populations and unvaccinated populations (H.R. 1757), E576 [26AP]

Diseases: preserve effectiveness of medically important antimicrobials used in treatment of human and animal diseases (H.R. 1150), H2991, H2992 [3JN], H6623 [16OC], E299 [14MR]

——— require group and individual health insurance coverage and group health plans to cover oral cancer drugs on terms no less favorable than for cancer medications administered by a health care provider (H.R. 1801), H2256 [24AP], H7199 [19NO]

Drugs: address prescription drug abuse, H1873 [10AP]

——— reschedule marijuana under the Controlled Substances Act and allow for medicinal use of marijuana in accordance with State laws (H.R. 689), E150 [14FE]

FDA: decision to allow over-the-counter access to emergency-contraceptive drug Plan B One Step without age restriction, H3639 [14JN]

——— encourage use of abuse-deterrent formulations of drugs (H. Res. 161), H2030 [16AP]

——— prohibit wholesalers from purchasing prescription drugs from pharmacies and enhance information and transparency of drug wholesalers engaged in interstate commerce, E784 [4JN]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (S. 622), H2984–H2993 [3JN], E829 [10JN]

——— strengthen and secure the pharmaceutical distribution supply chain to protect consumers from counterfeit pharmaceuticals, H5961, H5962, H5965 [28SE]

——— strengthen and secure the pharmaceutical distribution supply chain to protect consumers from counterfeit pharmaceuticals (H.R. 1919), H2968–H2984 [3JN], E784, E796 [4JN], E883 [17JN]

——— strengthen and secure the pharmaceutical distribution supply chain to protect consumers from counterfeit pharmaceuticals (S. 957), H2979 [3JN]

——— strengthen regulation of compounding drugs by pharmacies, H5961, H5962, H5965 [28SE]

——— strengthen regulation of compounding drugs by pharmacies (H.R. 3019), E1223 [2AU]

——— strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), H5946–H5965 [28SE]

——— urge approval of drug to treat Duchenne Muscular Dystrophy, H5078 [25JY], E1223 [2AU]

Health: address issues relative to drug resistant diseases in developing countries, E537 [24AP]

India: address actions that infringe upon U.S. intellectual property rights, H7170 [18NO]

Medicare: prevent budget sequestration from impacting payment for physician-administered drugs (H.R. 1416), H1867 [10AP]

——— reform, H437 [12FE]

——— tribute to part D prescription drug benefit program, H3369 [13JN]

New Jersey: tribute to biopharmaceutical and medical technology companies for Hurricane Sandy relief efforts, H1919 [11AP]

Orphan Drug Act: anniversary, E13 [4JA]

Patient Protection and Affordable Care Act: impact, H1349 [12MR], H1641 [20MR], H2168 [23AP], H2492 [8MY], H2610 [15MY], H2666 [16MY]

——— impact on tax burden, H64 [14JA], H822 [4MR], H1336 [12MR], H6532 [11OC]

Pharmacies: ensure and foster safety and quality of care and competitive marketplace by exempting independent pharmacies from antitrust laws in negotiations with health and health insurance providers (H.R. 1188), H5040–H5044 [24JY]

Small business: tribute to community pharmacies, E1154 [30JY]

Social Security: reform, H2715 [16MY]

Taxation: include vaccines against seasonal influenza within the definition of taxable vaccines (H.R. 475), H3704, H3705 [18JN]

Remarks in Senate

Dept. of HHS: award certain asthma-related grants to States that permit trained school personnel to administer epinephrine (H.R. 2094), S7778 [31OC]

——— award certain asthma-related grants to States that permit trained school personnel to administer epinephrine (S. 1503), S6448 [12SE]

——— develop an antimicrobial resistance research strategic plan, S6866 [24SE]

——— provide States with incentives to require elementary and secondary schools to maintain, and permit school personnel to administer, epinephrine, S3525 [15MY]

Dept. of Justice: provide the Depts. of Defense and Veterans Affairs authority to establish a prescription drug take-back program for Armed Forces members and veterans, S8438 [21NO]

——— provide the Depts. of Defense and Veterans Affairs authority to establish a prescription drug take-back program for Armed Forces members and veterans (S. 1089), S3957 [4JN]

Diseases: preserve effectiveness of medically important antimicrobials used in treatment of human and animal diseases (S. 1256), S5503 [27JN]

Drugs: establish a commission to coordinate efforts to reduce prescription drug abuse (S. 1277), S5706 [16JY]

——— increase Federal oversight of prescription opioid treatment and assistance to States in reducing opioid abuse, diversion, and deaths (S. 348), S779 [14FE]

FDA: allow fast track approval of certain orphan drugs, S3002 [25AP]

——— clarify regulation of animal drug compounding, S8071, S8072 [18NO]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (S. 622), S3275 [8MY]

——— strengthen regulation of compounding drugs by pharmacies (H.R. 2186), S7967 [13NO]

——— strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), S7800 [4NO], S7802 [5NO], S7864 [6NO], S8026–S8030 [14NO], S8071–S8076, S8079, S8080 [18NO]

——— strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), motion to proceed, S7846 [6NO], S7938, S7940–S7944 [12NO], S7965, S7967–S7970, S7974, S7981, S7985 [13NO], S8013, S8024 [14NO]

——— strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), unanimous-consent agreement, S8071 [18NO]

——— strengthen regulation of human drug compounding and drug supply chain security (H.R. 3204), unanimous-consent request, S7984, S7985 [13NO], S8029, S8030 [14NO]

Medicare: deliver a meaningful drug benefit and lower prescription drug prices (S. 408), S1015 [28FE]

——— expansion of Part D, S6875, S6876 [24SE]

——— extended coverage of immunosuppressive drugs for kidney transplant patients and other renal dialysis provisions (S. 323), S714 [13FE]

——— permit direct payment to pharmacies for certain compounded drugs for a specific beneficiary for use through an implanted infusion pump (S. 914), S3330 [9MY]

——— require drug manufacturers to provide rebates for drugs dispensed to low-income individuals under the prescription drug benefit program (S. 740), S2687 [16AP]

Mental health: reauthorize and improve programs related to mental health and substance use disorders, S2730 [17AP], S2781 [18AP]

National Association of Chain Drug Stores: observance of RxIMPACT Day, S1707 [12MR]

National Medicine Abuse Awareness Month: observance, S7611 [29OC], S7668 [30OC]

Patient Protection and Affordable Care Act: eliminate cap on flexible spending account contributions and requirement for prescriptions for over-the-counter drugs under health savings accounts and flexible spending accounts, S2302 [22MR]

——— impact, S2078 [21MR], S2320 [22MR], S3100–S3102 [7MY]

——— impact on tax burden, S8659 [11DE]

Senate: legislative priorities, S7563–S7565 [28OC]

Social Security: historical context of Republican Congressional opposition to instituting Social Security and Medicare relative to Patient Protection and Affordable Care Act implementation, S6875 [24SE]

Taxation: include vaccines against seasonal influenza within the definition of taxable vaccines (H.R. 475), S4725 [19JN]

——— include vaccines against seasonal influenza within the definition of taxable vaccines (H.R. 475), unanimous-consent agreement, S2904 [23AP]

Veterinarians: allow transport and dispensing of controlled substances in the usual course of veterinary practice outside of the registered location (S. 1171), S4523 [17JN]

——— allow transport and dispensing of controlled substances in the usual course of veterinary practice outside of the registered location (S. 950), S9043 [19DE]

Reports

Benefits of the Health Care Reform Law in Arkansas’ 2d Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4551 [17JY]

Benefits of the Health Care Reform Law in Florida’s 12th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4553 [17JY]

Benefits of the Health Care Reform Law in Georgia’s 11th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4569 [17JY]

Benefits of the Health Care Reform Law in Indiana’s 9th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4559 [17JY]

Benefits of the Health Care Reform Law in Michigan’s 10th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4567 [17JY]

Benefits of the Health Care Reform Law in Minnesota’s 3d Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4559 [17JY]

Benefits of the Health Care Reform Law in Ohio’s 16th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4554 [17JY]

Benefits of the Health Care Reform Law in Pennsylvania’s 18th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce•20(House) Democratic Staff, H4552 [17JY]

Benefits of the Health Care Reform Law in Tennessee’s 1st Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4560 [17JY]

Benefits of the Health Care Reform Law in Tennessee’s 6th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4570 [17JY]

Benefits of the Health Care Reform Law in Tennessee’s 7th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4556 [17JY]

Benefits of the Health Care Reform Law in Texas’ 8th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4548 [17JY]

Benefits of the Health Care Reform Law in Texas’ 26th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4542 [17JY]

Benefits of the Health Care Reform Law in Virginia’s 5th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4562 [17JY]

Benefits of the Health Care Reform Law in Virginia’s 7th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4565 [17JY]

Benefits of the Health Care Reform Law in Washington’s 5th Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4566 [17JY]

Benefits of the Health Care Reform Law in Wisconsin’s 1st Congressional District: Committees on Energy and Commerce, Ways and Means, and Education and the Workforce (House) Democratic Staff, H4548 [17JY]

Reports filed

FDA User Fee Programs Relating to New Animal Drugs and Generic New Animal Drugs Reauthorization: Committee on Health, Education, Labor, and Pensions (Senate) (S. 622), S2025 [20MR]

FDA User Fee Programs Relating to New Animal Drugs Reauthorization: Committee on Energy and Commerce (House) (H.R. 1407) (H. Rept. 113–188), H5395 [2AU]

Medical Preparedness Allowable Use Act: Committee on Homeland Security (House) (H.R. 1791) (H. Rept. 113–273), H7352 [21NO]

Mental Health Awareness and Improvement Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 689), S2589 [11AP]

Pharmaceutical Compounding Quality and Accountability Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 959), S4673 [19JN]

Safeguarding America’s Pharmaceuticals Act: Committee on Energy and Commerce (House) (H.R. 1919) (H. Rept. 113–93), H3014 [3JN]

School Access to Emergency Epinephrine Act: Committee on Energy and Commerce (House) (H.R. 2094) (H. Rept. 113–182), H5172 [30JY]

——— Committee on Health, Education, Labor, and Pensions (Senate) (H.R. 2094), S7673 [30OC]

Statements

Safeguarding America’s Pharmaceuticals Act: Pew Charitable Trust, H2981 [3JN]

Texts of

H.R. 475, include vaccines against seasonal influenza within the definition of taxable vaccines, H3704 [18JN]

H.R. 1911, Safeguarding America’s Pharmaceuticals Act, H2969–H2978 [3JN]

H.R. 2094, School Access to Emergency Epinephrine Act, H5145 [30JY]

H.R. 3204, Drug Quality and Security Act, H5946–H5960 [28SE]

S. 323, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act, S715 [13FE]

S. 408, Medicare Prescription Drug Savings and Choice Act, S1016 [28FE]

S. 622, FDA reauthorization of user fee programs relating to new animal drugs and generic new animal drugs, S3275–S3282 [8MY]

S. 622, FDA user fee programs relating to new animal drugs and generic new animal drugs reauthorization, H2984–H2991 [3JN]

S. 1503, School Access to Emergency Epinephrine Act, S6449 [12SE]

S. Res. 97, FDA encouragement of use of abuse-deterrent formulations of drugs, S2654 [15AP]